Lumexa Imaging (NASDAQ:LMRI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Lumexa Imaging (NASDAQ:LMRI) from a hold rating to a buy rating in a research report report published on Saturday morning,Wall Street Zen reports.

A number of other equities analysts have also commented on LMRI. Raymond James Financial set a $17.00 target price on shares of Lumexa Imaging in a research report on Monday, September 28th. KeyCorp initiated coverage on Lumexa Imaging in a research note on Thursday, September 24th. They issued an “overweight” rating and a $18.00 price objective on the stock. Barclays lifted their target price on Lumexa Imaging from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Friday, August 28th. UBS Group reissued a “strong-buy” rating on shares of Lumexa Imaging in a research report on Monday, September 28th. Finally, Deutsche Bank Aktiengesellschaft set a $16.00 price target on Lumexa Imaging in a research note on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $16.40.

Lumexa Imaging Stock Up 4.4%

Shares of LMRI opened at $10.77 on Friday. The firm has a fifty day moving average price of $11.29 and a 200-day moving average price of $10.27. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 1.40. The firm has a market capitalization of $1.03 billion and a P/E ratio of -21.98. Lumexa Imaging has a 12-month low of $6.45 and a 12-month high of $19.45.

Lumexa Imaging (NASDAQ:LMRI) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.03 by $0.17. The company had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Equities research analysts expect that Lumexa Imaging will post 0.25 earnings per share for the current year.

Institutional Trading of Lumexa Imaging

Several hedge funds and other institutional investors have recently bought and sold shares of LMRI. Strs Ohio purchased a new position in Lumexa Imaging in the first quarter valued at about $38,000. PNC Financial Services Group Inc. acquired a new position in Lumexa Imaging during the 1st quarter valued at approximately $63,000. Principal Financial Group Inc. raised its stake in Lumexa Imaging by 1.2% in the 1st quarter. Principal Financial Group Inc. now owns 664,136 shares of the company’s stock worth $5,712,000 after acquiring an additional 7,875 shares during the last quarter. State of Wyoming acquired a new stake in shares of Lumexa Imaging during the first quarter worth about $91,000. Finally, AXQ Capital LP acquired a new stake in Lumexa Imaging during the 2nd quarter valued at approximately $128,000.

About Lumexa Imaging

Lumexa Imaging, Inc (NASDAQ: LMRI) is a U.S. healthcare services company focused on outpatient diagnostic imaging. The company operates and supports imaging centers that provide noninvasive services used to detect, diagnose and monitor medical conditions.

Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and other diagnostic imaging procedures. Lumexa also works with radiologists and referring healthcare providers to deliver image interpretation and related clinical services.

The company’s operations are primarily located in the United States, serving patients through a network of outpatient imaging facilities and affiliated radiology practices.